Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.

By L. Kyne, M. Warny, A. Qamar, C. Kelly. The Lancet, 2001

835 citations recorded by the source corpus.

Subfields: Critical Care and Intensive Care Medicine, Gastroenterology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/481e3000d190b5b53be6e79e8905ac2891f027ce

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

Citations in the corpus

Clostridium difficile infection: new developments in epidemiology and pathogenesis (2009, background): “1 ); this lack of immune response has also been associated with a higher rate of recurrent diseas”
Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. (2008, neutral): “difficile toxin [11].”
Treatment with monoclonal antibodies against Clostridium difficile toxins. (2010, neutral): “Yes 2/25 (8) 6/19 (32) 24 (1 to 50) 0.06 No† 4/52 (8) 11/55 ( 20 ) 12 (−1 to 26) 0.09”
Antimicrobial-associated risk factors for Clostridium difficile infection. (2008, background): “In one study, patients who did not develop increased serum anti-toxin A IgG titers in response to their first episode of CDI were 48 times as likely to develop recurrent CDI than patients who mounted an adequate immune response [30].”
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). (2018, neutral): “toxins, advancing age, and increasingly severe underlying disease [81, 343].”
Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. (2005, background): “difficile toxin A and age of 165 years were associated with recurrences; baseline and day 12 anti–toxin A IgG concentrations did not differ on the basis of age, but power was limited in these studies [22, 23].”
Recommendations for Surveillance of Clostridium difficile–Associated Disease (2007, background): “difficile toxins A and B.(35,36) However, protection is also observed in humans and ani mal models when colonization occurs with nontoxigenic strains.”
Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. (2005, background): “Among patients who receive antibiotics, several risk factors have been identified as potentially enhancing the risk of developing CDAD: advanced age, comorbidities, duration of hospitalization, stay in intensive care units, administration of antiulcer medications, use of laxatives, tube feeding, a p”
European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. (2014, background): “[117] Metronidazole 632 98 6 92 Vancomycin 122 99 10 89 [57] Metronidazole 44 ? 50 – [118] Metronidazole 99 62 ? – [119] Metronidazole 207 78 28 56 [68] Metronidazole 1123 84 29 60 Vancomycin 112 ? 28 [120] Fidaxomicin varying dose 45 91 5 86”